Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Abraham, E

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. [electronic resource] - Critical care medicine Mar 2001 - 503-10 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0090-3493

10.1097/00003246-200103000-00006 doi


APACHE
Adolescent
Adult
Aged
Aged, 80 and over
Canada--epidemiology
Double-Blind Method
Drug Monitoring
Europe--epidemiology
Female
Humans
Immunoglobulin G--immunology
Immunoglobulin Heavy Chains
Immunoglobulin gamma-Chains
Interleukin-6--blood
Male
Middle Aged
Multiple Organ Failure--microbiology
Receptors, Tumor Necrosis Factor--immunology
Recombinant Fusion Proteins--immunology
Sepsis--blood
Severity of Illness Index
Shock, Septic--blood
United States--epidemiology